Fig. 12.
COSMIC-312: cabozantinib + atezolizumabin in first line (Japan dose not join). Clinical trial information: NCT03755791 [39].
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.